Government

Quick access to information based on government's structure



Ministry of Health

BC PharmaCare wants to hear Your Voice.

On this page...

Overview

Through this website, patients, caregivers, and patient groups can add their voice to the BC PharmaCare drug review process. It is part of our commitment to give British Columbians a chance to share their perspectives on drug decisions that affect them.

Please take a look at the list of drugs that are now under review by the Ministry of Health and notice the medical condition for which each drug is used. If you are eligible to give input, you can fill out an online questionnaire for consideration by the Drug Benefit Council as part of their review.  (Tell me how my input will be used…)

Please note that, as part of the questionnaire, you will be required to declare any Conflicts of Interest. (Tell me about the Conflict of Interest Guidelines…)

Your privacy is fully protected. (Tell me more about privacy protection.) Your responses will be separated from your identifying information before being provided to the Drug Benefit Council.

For patient groups that are providing input: Only the name of your organization will be forwarded to the Drug Benefit Council.

Who can give input?

If you are a B.C. resident and answer yes to any of the following questions for a drug listed in the table below, you can give your input:

  1. Do you have the medical condition for which the drug would be used?
  2. Are you a caregiver to someone who has that medical condition?
  3. Does your patient group represent patients who have that medical condition AND have you registered with PharmaCare to give input?  (Learn more about registering your organization).

Which drugs are being reviewed?

Below is a list of drugs that are, or soon will be, open for input.

If you are eligible to give input (see above):

  1. Read about the drug by clicking on the drug’s information sheet link in the table below.
  2. If you would like to prepare your answers beforehand, review the printable sample questionnaire for
    a) patients (PDF 45K ), b) caregivers (PDF 65K ) or c) patient groups (PDF 94K ). When you are ready, return to this web page to take the survey.
  3. Click the appropriate “Take the survey” link.
    Note: the links appear only when the drug is open for input.
Drug Name What this drug is for When you can take part Take the survey

aripiprazole (Abilify Maintena™)

Abilify Maintena™ is used for maintenance treatment of schizophrenia. Schizophrenia is an illness of the brain that affects a person's senses and thought processes.

For more information, see this drug information sheet.
from Oct 22, 2014, until Nov 19, 2014 at midnight

icatibant (Firazyr®)

Firazyr® is used for treating acute attacks of hereditary angioedema (HAE) in adults who have a deficiency in the protein C1-esterase inhibitor.

For more information, see this drug information sheet.
from Oct 22, 2014, until Nov 19, 2014 at midnight

indacaterol-glycopyrronium (Ultibro® Breezehaler®)

Ultibro® Breezehaler® is used to treat breathing difficulties due to a lung disease called Chronic Obstructive Pulmonary Disease (COPD). It is not used to treat sudden, severe symptoms of COPD.

For more information, see this drug information sheet.
from Oct 22, 2014, until Nov 19, 2014 at midnight

ivacaftor (Kalydeco®)

Kalydeco® is used to treat cystic fibrosis in patients 6 years of age or older who have a specific type of genetic mutation.

For more information, see this drug information sheet.
from Oct 22, 2014, until Nov 19, 2014 at midnight
Having technical difficulties in submitting your input?
Contact us for assistance by e-mail at pim@gov.bc.ca.

Can you notify me when public input is being accepted for a drug?

Yes. We can send you an e-mail when other drugs are being reviewed. Just sign up for our subscription service.

How do I find out about PharmaCare's coverage decision for a specific drug?

After the Drug Benefit Council provides its formal recommendation to the Ministry of Health, the Ministry reviews the recommendation and makes a coverage decision in the context of existing policies, programs, priorities and resources.

To find out when a decision will be made about PharmaCare coverage for a specific drug, visit our Drug Review Results section.